BioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.1 SEK | +2.91% | +3.25% | +25.59% |
Jun. 05 | BioGaia AB Establishes Its Own Distribution in Australia and New Zealand | CI |
May. 07 | Nordic Shares Closed Up Tuesday; Storskogen Group Series B Topped Leaders | DJ |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.59% | 1.18B | |
+7.46% | 101B | |
+8.42% | 42.18B | |
-13.04% | 32.26B | |
+80.80% | 29.79B | |
-10.92% | 16.06B | |
+1.93% | 14.45B | |
-6.77% | 12.01B | |
+177.16% | 10.71B | |
+4.12% | 8.89B |
- Stock Market
- Equities
- BIOG B Stock
- News BioGaia AB
- Biogaia AB Appoints Theresa Agnew as CEO